NCT00908921View on ClinicalTrials.gov

Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

PHASE4CompletedINTERVENTIONAL
Enrollment

391

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GLIMEPIRIDE

Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Shanghai

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00908921 - Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter | Biotech Hunter